Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and QT Interval Effects of FCN-437c in Healthy Subjects
NCT06290466Phase 1Completed
- Sponsor
- Jinzhou Ahon Pharmaceutical Co., Ltd.
- Start
- Nov 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ongiciclib in breast cancer (3 arms), sponsored by Jinzhou Ahon Pharmaceutical Co., Ltd. Primary endpoint: Change from baseline in QTcF interval compared to placebo. Started Nov 2022; status: completed.
02
Drugs
ongiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06290466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06290466.